Don Morris

4.7k total citations · 1 hit paper
91 papers, 3.3k citations indexed

About

Don Morris is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Don Morris has authored 91 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 28 papers in Genetics and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Don Morris's work include Virus-based gene therapy research (26 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Don Morris is often cited by papers focused on Virus-based gene therapy research (26 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Don Morris collaborates with scholars based in Canada, United States and Tanzania. Don Morris's co-authors include Daniel Shoemaker, Ronald W. Davis, Deval Lashkari, Chandini M. Thirukkumaran, Peter Forsyth, Naiping Shen, Earl Hubbell, Nila Shah, Michael J. Kozal and Daniel E. Meyers and has published in prestigious journals such as Nature Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Don Morris

89 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Don Morris	1.4k	1.1k	907	570	409	91	3.3k
G W Demers	1.8k 1.3×	1.7k 1.6×	700 0.8×	324 0.6×	145 0.4×	29	3.6k
Scott A. Foster	2.4k 1.8×	1.5k 1.3×	603 0.7×	650 1.1×	149 0.4×	63	4.9k
Vincent Maréchal	2.0k 1.4×	2.1k 1.9×	247 0.3×	889 1.6×	251 0.6×	72	4.0k
Craig P. Webb	2.4k 1.8×	623 0.6×	688 0.8×	161 0.3×	630 1.5×	46	3.7k
Christoph Springfeld	634 0.5×	2.2k 2.0×	658 0.7×	249 0.4×	941 2.3×	118	3.7k
Sharon Bodrug	2.1k 1.6×	786 0.7×	327 0.4×	352 0.6×	102 0.2×	28	3.2k
Luigi Aurisicchio	1.4k 1.1×	966 0.9×	585 0.6×	363 0.6×	437 1.1×	107	3.0k
Franco M. Buonaguro	1.3k 1.0×	719 0.7×	205 0.2×	202 0.4×	294 0.7×	111	3.4k
Robson Q. Monteiro	1.8k 1.3×	544 0.5×	822 0.9×	457 0.8×	199 0.5×	116	4.0k

Countries citing papers authored by Don Morris

Since Specialization

Citations

This map shows the geographic impact of Don Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Morris more than expected).

Fields of papers citing papers by Don Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Morris. The network helps show where Don Morris may publish in the future.

Co-authorship network of co-authors of Don Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Don Morris. A scholar is included among the top collaborators of Don Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Morris. Don Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →

Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations

Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations

Gibson, Adam, Daniel E. Meyers, Michael Dean, et al.. (2021). P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients. Journal of Thoracic Oncology. 16(3). S348–S348.

Dharmani‐Khan, Poonam, Ahsan Chaudhry, Tyler Williamson, et al.. (2021). A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. Cytotherapy. 23(11). 1007–1016. 5 indexed citations

Fung, Andrea S., Karen Kopciuk, Michelle L. Dean, et al.. (2021). CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients. PLoS ONE. 16(1). e0241240–e0241240. 6 indexed citations

Mostafa, Ahmed, Daniel E. Meyers, Chandini M. Thirukkumaran, et al.. (2018). Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. Cancers. 10(6). 205–205. 43 indexed citations

Thakur, Satbir, Haocheng Li, Angela Chan, et al.. (2018). The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer. PLoS ONE. 13(1). e0188983–e0188983. 42 indexed citations

Henning, Jan‐Willem, Elizabeth Kurien, Don Morris, et al.. (2018). Surgical excision versus observation as initial management of desmoid tumors: A population based study. European Journal of Surgical Oncology. 45(4). 699–703. 30 indexed citations

10.

Dharmani‐Khan, Poonam, Joanne Luider, Don Morris, et al.. (2018). Anti-thymocyte globulin’s activity against acute myeloid leukemia stem cells. Bone Marrow Transplantation. 54(4). 549–559. 6 indexed citations

11.

Kornaga, Elizabeth, Alexander C. Klimowicz, Travis Ogilvie, et al.. (2016). A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Modern Pathology. 29(8). 799–809. 19 indexed citations

12.

McIntyre, John B., Gregg Nelson, Prafull Ghatage, et al.. (2013). PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. Gynecologic Oncology. 132(1). 188–193. 21 indexed citations

13.

Nelson, Gregg, Sandra Lee, Guangming Han, et al.. (2013). MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecologic Oncology. 131(2). 309–314. 40 indexed citations

14.

Thirukkumaran, Chandini M., Zhong Qiao Shi, Joanne Luider, et al.. (2012). Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma. Clinical Cancer Research. 18(18). 4962–4972. 60 indexed citations

15.

Lawson, Keith A. & Don Morris. (2012). Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?. Expert Opinion on Biological Therapy. 12(7). 891–903. 7 indexed citations

16.

Klimowicz, Alexander C., Karen Kopciuk, Stephanie Petrillo, et al.. (2011). CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(7). 1169–1178. 60 indexed citations

17.

Chow, Lorraine, Nizar J. Bahlis, Jeffrey A. Russell, et al.. (2005). Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplantation. 36(7). 591–596. 12 indexed citations

18.

Bewick, Mary A., Michael Conlon, Robert M. Lafrenie, et al.. (1999). Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplantation. 24(4). 377–384. 23 indexed citations

19.

Shoemaker, Daniel, et al.. (1996). Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar–coding strategy. Nature Genetics. 14(4). 450–456. 413 indexed citations

20.

Jenkins, J. Stephen, Greg C. Flaker, Leigh Ann Price, et al.. (1994). Causes of higher in-hospital mortality in women than in men after acute myocardial infarction. The American Journal of Cardiology. 73(5). 319–322. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact